Prognostic Impact of the Presence of Barrett's Esophagus and Intestinal Metaplasia on Esophageal Adenocarcinoma Survival.
Barrett’s esophagus
esophageal adenocarcinoma
intestinal metaplasia
Journal
Foregut (Thousand Oaks, Calif.)
ISSN: 2634-5161
Titre abrégé: Foregut
Pays: United States
ID NLM: 9918266300406676
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
entrez:
29
12
2022
pubmed:
30
12
2022
medline:
30
12
2022
Statut:
ppublish
Résumé
Barrett's esophagus (BE), defined by the presence of intestinal metaplasia (IM) on histology, is thought to be the only identifiable precursor lesion for esophageal adenocarcinoma (EAC). Recent studies have suggested the possibility of an alternate, non-IM associated EAC that is a more aggressive form of EAC with worse survival. Among EAC patients, we aimed to compare survival of patients with and without IM at the time of diagnosis. This was a retrospective cohort study of all patients with histologic confirmed EAC evaluated at a tertiary care center from 2013 to 2019. Cases were categorized according to the presence or absence of IM on histologic specimens (Group I-IM-EAC and Group II-non-IM-EAC). We compared demographic characteristics, clinical stage, therapy, and survival between the 2 groups using the Chi-square and ANOVA tests (for categorical and continuous variables, respectively). We used Cox proportional hazards regression to determine the association of IM with overall survival, adjusting for sex, age at diagnosis, tumor location, histologic grade, and clinical stage. A total of 475 patients were included in this analysis (mean age 64.8 years [SD 10.8], 89% white) and 109 (23.0%) had no evidence of IM. Compared with IM-EAC (Group I), individuals in the non-IM-EAC group were younger ( EAC without the presence of IM on histology was associated with worse survival compared to those with IM. Future prospective studies with detailed molecular sequencing are required to clarify if 2 separate phenotypes of EAC exist (IM-EAC and non-IM-EAC). If confirmed, this may have significant implications for screening and management strategies.
Sections du résumé
Background/Aims
UNASSIGNED
Barrett's esophagus (BE), defined by the presence of intestinal metaplasia (IM) on histology, is thought to be the only identifiable precursor lesion for esophageal adenocarcinoma (EAC). Recent studies have suggested the possibility of an alternate, non-IM associated EAC that is a more aggressive form of EAC with worse survival. Among EAC patients, we aimed to compare survival of patients with and without IM at the time of diagnosis.
Methods
UNASSIGNED
This was a retrospective cohort study of all patients with histologic confirmed EAC evaluated at a tertiary care center from 2013 to 2019. Cases were categorized according to the presence or absence of IM on histologic specimens (Group I-IM-EAC and Group II-non-IM-EAC). We compared demographic characteristics, clinical stage, therapy, and survival between the 2 groups using the Chi-square and ANOVA tests (for categorical and continuous variables, respectively). We used Cox proportional hazards regression to determine the association of IM with overall survival, adjusting for sex, age at diagnosis, tumor location, histologic grade, and clinical stage.
Results
UNASSIGNED
A total of 475 patients were included in this analysis (mean age 64.8 years [SD 10.8], 89% white) and 109 (23.0%) had no evidence of IM. Compared with IM-EAC (Group I), individuals in the non-IM-EAC group were younger (
Conclusions
UNASSIGNED
EAC without the presence of IM on histology was associated with worse survival compared to those with IM. Future prospective studies with detailed molecular sequencing are required to clarify if 2 separate phenotypes of EAC exist (IM-EAC and non-IM-EAC). If confirmed, this may have significant implications for screening and management strategies.
Identifiants
pubmed: 36578279
doi: 10.1177/26345161211033277
pmc: PMC9793872
mid: NIHMS1816383
doi:
Types de publication
Journal Article
Langues
eng
Pagination
356-364Subventions
Organisme : NIDDK NIH HHS
ID : T32 DK007038
Pays : United States
Références
Nat Rev Gastroenterol Hepatol. 2009 Dec;6(12):724-37
pubmed: 19884893
Gastroenterology. 1995 Nov;109(5):1541-6
pubmed: 7557137
Dig Dis Sci. 2018 Aug;63(8):1988-1996
pubmed: 29671158
Gastroenterology. 2018 Jun;154(8):2068-2086.e5
pubmed: 29458154
Gastroenterology. 2020 Dec;159(6):2238-2240.e4
pubmed: 32777286
Gastroenterology. 2017 Sep;153(3):657-673.e1
pubmed: 28716721
Am J Gastroenterol. 2016 Jan;111(1):30-50; quiz 51
pubmed: 26526079
Gastroenterology. 2018 May;154(6):1594-1601
pubmed: 29577931
Gastroenterology. 2018 Jan;154(2):390-405
pubmed: 28780073
Ann Cardiothorac Surg. 2017 Mar;6(2):119-130
pubmed: 28447000
Gastrointest Endosc. 2019 Sep;90(3):335-359.e2
pubmed: 31439127
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Dis Esophagus. 2007;20(1):36-41
pubmed: 17227308
Dis Esophagus. 2010 Aug;23(6):451-7
pubmed: 20353441
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2710-2716.e1
pubmed: 31712077
Gastroenterology. 2018 Dec;155(6):1720-1728.e4
pubmed: 30165050
Gastroenterology. 2020 May;158(6):1682-1697.e1
pubmed: 32032585
Gastroenterology. 2017 Sep;153(3):646-648
pubmed: 28712761